Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents

@article{Steinman2006NarrativeRT,
  title={Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents},
  author={Michael A. Steinman and Lisa A. Bero and Mary-Margaret Chren and C. Seth Landefeld},
  journal={Annals of Internal Medicine},
  year={2006},
  volume={145},
  pages={284-293}
}
Key Summary Points Industry promoted gabapentin for on- and off-label uses as part of a comprehensive marketing plan. Frequent prescribers of anticonvulsant agents, opinion leaders, and local champions of gabapentin were specially targeted for promotion. Gabapentin was promoted by using education and research, activities not typically recognized as promotional. Independent continuing medical education, peer-to-peer selling by physician speakers, industry-funded studies, and publications in the… 

Disseminating Findings from a Drug Class Review: Using Best Practices to Inform Prescription of Antiepileptic Drugs for Bipolar Disorder

An effort to use counter-marketing strategies to compete with those implemented by the pharmaceutical industry and to help clinicians make use of available evidence to inform their prescription of antiepileptic drugs in the treatment of bipolar disorder is described.

Often Off-label: Questionable Gabapentinoid Use Noted at Hospital Admission Warrants Deprescribing.

There is an opportunity to deprescribe gabapentinoids on the basis of few gabAPentinoid users having a documented indication and the recent research showing potentials for harm and abuse, according to Gingras et al.

Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?

Clinicians should exercise rigorous appraisal of the available evidence for a given indication, and researchers should conduct larger, higher-quality studies to better assess the efficacy of gabapentin for many of its off-label uses.

A Clinical Overview of Off-label Use of Gabapentinoid Drugs.

Clinicians who prescribe gabapentinoids off-label for pain should be aware of the limited evidence and should acknowledge to patients that potential benefits are uncertain for most off- label uses.

The Rise and Fall of Gabapentin for Bipolar Disorder: A Case Study on Off-Label Pharmaceutical Diffusion

Evidence of inefficacy and/or the cessation of pharmaceutical marketing, and a restrictive formulary policy can alter prescriber behavior away from targeted pharmacologic treatments, suggest that both information and policy are important means in altering physician prescribing behavior.

Between evidence and commerce – the case of sufentanil sublingual tablet systems

It is concluded that involving physicians in research and publication helped industry to engage opinion leaders, reward customers and influence prescribing, and because of the recent, seemingly omnipresent, advertisements for the sufentanil sublingual tablet system (SSTS), it was prudent to gather more information about how the data presented in van de Donk et al.

Gabapentin in the Treatment of Mental Illness: The Echo Chamber of the Case Series

The number of reports and their distribution in many different journals created a type of "echo chamber" effect, through which the sheer number of publications and citations may give legitimacy to the practice of using gabapentin for bipolar disorder.

The promotion of olanzapine in primary care: an examination of internal industry documents.

  • G. Spielmans
  • Medicine, Psychology
    Social science & medicine
  • 2009

Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship

The hypothesis that bias affects review articles regarding rimonabant, an anti-obesity drug that blocks the central cannabinoid receptor, is tested and findings are characteristic of bias that arises from financial conflicts of interest, and suggestive of ghostwriting by a common author.

Outcome reporting in industry-sponsored trials of gabapentin for off-label use.

Examination of reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis for off-label indications found selective outcome reporting threatens the validity of evidence for the effectiveness of off- label interventions.
...

References

SHOWING 1-10 OF 107 REFERENCES

Efficacy of gabapentin as adjunctive therapy in a large, multicenter study

The results of the study demonstrate that gabapentin is effective as adjunctive therapy in patients with partial seizures whose seizures are inadequately controlled by traditional AEDs.

Treatment of chronic pain with antiepileptic drugs: a new era.

  • H. Hansen
  • Medicine, Psychology
    Southern medical journal
  • 1999
Of the newer AEDs, gabapentin shows the greatest potential and appears to be well tolerated by patients, and further research is required to identify the role of various agents and their effect on patient return to function and quality of life.

Treatment of chronic pain with antiepileptic drugs: a new era.

Of the newer AEDs, gabapentin shows the greatest potential and appears to be well tolerated by patients, and further research is required to identify the role of various agents and their effect on patient return to function and quality of life.

Gabapentin for Treatment of Pain and Tremor: A Large Case Series

  • M. D. Merren
  • Medicine, Psychology
    Southern medical journal
  • 1998
Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated.

Health industry practices that create conflicts of interest: a policy proposal for academic medical centers.

More stringent regulation is necessary, including the elimination or modification of common practices related to small gifts, pharmaceutical samples, continuing medical education, funds for physician travel, speakers bureaus, ghostwriting, and consulting and research contracts.

A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures

Gabapentin at 900 or 1,800 mg/day is effective and safe as monotherapy for patients with newly diagnosed partial epilepsy and the most clinically relevant measure of retention on treatment (exit event plus adverse event withdrawal rate) was similar to that of carbamazepine.

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group.

The findings of this study did not demonstrate that gabapentin is an effective adjunctive treatment when administered to outpatients with bipolar disorder.

Accepting commercial sponsorship

An examination of the Royal College of Paediatrics and Child Health's resulting report and its recommendations may offer some help to other organisations struggling with the same issue.

Gabapentin and Lamotrigine: Novel Treatments for Mood and Anxiety Disorders

Gabapentin demonstrates promise for the treatment of panic and generalized anxiety, while both gabapentin and lamotrigine appear useful as mood stabilizers in the treatmentof bipolar disorder.

A Mechanistic Approach to Antiepileptic Drug Interactions

  • G. Anderson
  • Biology, Medicine
    The Annals of pharmacotherapy
  • 1998
By understanding the mechanisms of drug interactions, the pharmacist can play a key role in patient care by anticipating and preventing AED drug interactions.
...